Fig. 1: CONSORT Flow Diagram of the study. | npj Breast Cancer

Fig. 1: CONSORT Flow Diagram of the study.

From: Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

Fig. 1: CONSORT Flow Diagram of the study.

Among 696 patients assessed for eligibility in the ATEMPT trial, 512 were randomized to receive treatment with either adjuvant T-DM1 (n = 384, of which 383 received the intervention) or TH (n = 128, of which 114 received the intervention).

Back to article page